Newer drugs are more targeted than standard agents, but their incorporation into treatment regimens is challenging because of the risk of cardiovascular and infectious adverse events.
Janus kinase inhibitors effectively treat rheumatoid arthritis, but their use in smokers aged older than 65 years and certain other populations potentiates the risk of adverse events.
Patients who undergo a kidney transplant may face limitations in treatment options for diabetes mellitus because of the uncertainty of their renal function post transplantation.